E

East Coast Institute for Research | Jacksonville, FL

Research site
(Unclaimed)
Location
3550 University Boulevard South, Jacksonville, Florida, United States of America
Site insights

Top conditions

Diabetes Mellitus (13 trials)

Type 2 Diabetes Mellitus (11 trials)

Overweight (6 trials)

Obesity (6 trials)

Cardiovascular Diseases (5 trials)

Top treatments

LY3298176
Tirzepatide
Empagliflozin
Orforglipron
BI 456906
Bococizumab
LY3502970
Apixaban
EMPagliflozin
Relugolix

Parent organization

This site is a part of East Coast Institute for Research

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

12 of 38
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of this study is to determine the effect and safety of insulin efsitora alfa (LY3209590) compared to degludec in adult participants with...

Active, not recruiting
Diabetes
Type 2 Diabetes
Drug: Insulin Degludec
Drug: Insulin Efsitora Alfa

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Placebo
Drug: Apixaban Placebo

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-rela...

Active, not recruiting
Overweight or Obesity
Overweight
Drug: Placebo
Drug: Orforglipron
Locations recently updated

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Enrolling
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo

This study is open to adults who are at least 18 years old and havea body mass index (BMI) of 30 kg/m² or more, ora BMI of 27 kg/m² or more and at le...

Active, not recruiting
Obesity
Drug: Placebo
Drug: survodutide

The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on to...

Active, not recruiting
Chronic Kidney Disease
Drug: Matching placebo
Drug: Empagliflozin

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

This is a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. This st...

Active, not recruiting
Prostate Cancer
Drug: Leuprolide Acetate
Drug: Relugolix

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Dyslipidemias
Drug: Obicetrapib
Drug: Placebo

Trial sponsors

Lilly logo

Lilly (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems